Retrospective comparison of direct in-bore magnetic resonance imaging (MRI)-guided biopsy and fusion-guided biopsy in patients with MRI lesions which are likely or highly likely to be clinically significant prostate cancer

1

Multiparametric MRI (mpMRI) enhances the detection and localization of clinically significant prostate cancer (csPCa) compared to traditional TRUS biopsy.
2

Direct in-bore MR-guided biopsy (MRGB) accurately targets lesions but is time-consuming and less accessible than MRI-TRUS fusion-guided biopsy (FGB).
3

FGB combines mpMRI data with real-time TRUS images, allowing for a more efficient and cost-effective biopsy procedure while still detecting csPCa.
4

The study compares csPCa detection rates between FGB and MRGB, focusing on patients with prior negative TRUS biopsies and significant MRI lesions.
5

Statistical analysis was performed to assess differences in csPCa detection rates, with a significance threshold set at p ≤0.05.

World Journal Of Urology

by Wulphert Venderink, Marloes van der Leest, Annemarijke van Luijtelaar, Wendy J. M. van de Ven, Jurgen J. Fütterer, J. P. Michiel Sedelaar, Henkjan J. Huisman
September 4, 2017

1